Talphera (NasdaqGM:TLPH) Q4 2025 Earnings call March 23, 2026 11:00 AM ET Company ParticipantsJames Molloy - Managing Director, Equity ResearchJoao Teixeira - Associate Professor in Division of NephrologyShakil Aslam - Chief Medical OfficerSharon McMahon - Associate Professor of MedicineVincent Angotti - CEOConference Call ParticipantsEd Arce - Managing Director, Senior Research AnalystNazibur Rahman - VP and Biopharmaceuticals Equity Research AnalystYuan Zhi - Senior Equity Research AnalystModeratorGood mo ...

Talphera (NasdaqGM:TLPH) Q4 2025 Earnings call March 23, 2026 11:00 AM ET Speaker4Good morning, everyone, and welcome to the Talphera Virtual Analyst and Investor Event. At this time, all attendees are in a listen-only mode. A question and answer session will follow the formal presentations. As a reminder, this call is being recorded, and a replay will be made available on the Talphera website following the conclusion of the event. I'd now like to turn the call over to Vince Angotti, Chief Executive Officer ...

Core Insights - Talphera, Inc. will host a virtual investor and analyst event on March 23, 2026, to discuss Niyad® for continuous renal replacement therapy (CRRT) [1] - The event will feature principal investigators from the NEPHRO CRRT study, which evaluates Niyad's efficacy [1][2] Company Overview - Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for medically supervised settings [9] - The lead product candidate, Niyad, is a lyophilized formulation of nafamostat, which has received Breakthrough Device Designation from the FDA [9] Product and Study Details - Nafamostat is a broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, and potential antiviral properties, used in CRRT for over 30 years in Japan and South Korea [2] - Niyad aims to serve as a regional anticoagulant for patients who cannot tolerate heparin or are at risk of bleeding, addressing limitations of current anticoagulants [2] - The NEPHRO CRRT study is a prospective, double-blinded trial enrolling 70 adult patients in U.S. ICUs, focusing on the mean post-filter activated clotting time as the primary endpoint [7] Expert Involvement - Blaithin McMahon, PhD, and Joao Teixeira, MD, are principal investigators with extensive backgrounds in nephrology and critical care, contributing to the study's credibility [4][5]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 13, 2024 Registration No. 333-276562 Nuwellis, Inc. (Exact name of registrant as specified in its charter) Delaware 3845 68-0533453 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (I.R.S. Employer Identif ...